Immutep picks up more funds for LAG-3 oncology and autoimmune studies

Im­mutep has raised about $53 mil­lion to bankroll its LAG-3 drugs across on­col­o­gy and au­toim­mune dis­eases, giv­ing it a cash run­way to the first quar­ter of 2026.

The funds will bankroll a reg­is­tra­tional-di­rect­ed Phase III tri­al in lung can­cer, late-stage stud­ies in head and neck can­cer, and tri­al read­outs in metasta­t­ic and triple-neg­a­tive breast can­cer, chair Rus­sell Howard said in a state­ment. The cap­i­tal could al­so sup­port clin­i­cal en­try on the au­toim­mune front, the chair added.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN